Matched pair analysis comparing survival among patients who underwent allogeneic HSCT for first chronic phase chronic myeloid leukemia from 1999 to 2004
| Variable . | n . | Relative risk of death (95% CI) . | P . | 
|---|---|---|---|
| Main effect | |||
| No imatinib | 236 | 1.00* | |
| Imatinib | 143 | 0.48 (0.31-0.75) | .001† | 
| Variable . | n . | Relative risk of death (95% CI) . | P . | 
|---|---|---|---|
| Main effect | |||
| No imatinib | 236 | 1.00* | |
| Imatinib | 143 | 0.48 (0.31-0.75) | .001† |